Expected to be valued at US$ 4.6 billion by the end of 2023, the market for nasal polyposis treatment is likely to expand at a CAGR of 6.7% until 2033. By the conclusion of the 2023-2033 forecast period, a valuation of US$ 8.8 billion is anticipate for nasal polyposis treatment.
Growing prevalence of chronic rhinosinusitis with nasal polyps especially in elderly population is one of the major factors propelling industry growth. Surging inflammatory diseases around the world is also expected to contribute to growth of nasal polyposis market.
Advancements in technology for removal of nasal polyps and increase in research and development is expected to lead to novel therapeutic treatment for nasal polyps which will lead to market expansion.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 4.6 billion |
| Anticipated Forecast Value (2033) | US$ 8.8 billion |
| Projected Growth Rate (2023 to 2033) | CAGR 6.7% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market for Nasal Polyposis treatment was worth US$ 3.7 billion in 2018, while growing at a CAGR of 4.45% during the historical period. With each passing decade, extensive research & development activities are being conducted by healthcare professionals. These have translated into extensive clinical trials for potential drug candidates, or the introduction of novel therapies and diagnostics, which is expected to provide impetus to the market. For example, Hoffmann-La Roche completed its Phase III study on March 11, 2019, which was conducted to test effectiveness and safety of omalizumab in comparison with placebo in patients having chronic rhinosinusitis with nasal polyps who have witnessed insufficient response to standard treatments.
On the other hand, advancements in technology, such as nasal endoscopy and computerized tomography, better-quality healthcare facilities with innovative drug development for treatment of nasal polyps, and initiatives by governments in spreading awareness about nasal polyps, is expected to witness lucrative growth in market of Nasal polyposis during the projected period.
The growth in the number of rhinitis therapeutics distributed through the retail pharmacies and increasing number of these pharmacies in developed countries is anticipated to create opportunities and space for market expansion. In addition, patients generally opt for retail pharmacies for purchasing drugs, as these are easily accessible. Thus, presenting opportunities for future growth of nasal polyposis market.
After a comprehensive analysis of above-mentioned factors, the market for nasal polyposis is projected to attain a valuation of USD 8.8 billion by end of the forecast period, while exhibiting a CAGR of 6.7%.
The adoption of pipeline therapies in Nasal polyposis market like Fasenra (benralizumab), Tezepelumab, CBP-201, and others are expected to fuel growth of the market in the forecast period. With the launch of Fasenra (benralizumab) in 2022 and expected launch of Tezepelumab this year, the market is anticipated to witness growth during the forecast period. Both Fasenra and Tezepelumab is estimated to garner nearly USD 5 million in the first year of its launch which will aid in the expansion of targeted industry.
The recommendation from regulatory bodies for approval of authorised new drugs used in nasal polyposis treatment, is also anticipated to propel growth of this market, during the forecast period. For example, in June, 2020, Novartis got a positive recommendation on Xolair, its approved product. It is used for the treatment of adults who are suffering from serious chronic rhinosinusitis with nasal polyps. Likewise, Xolair is used for treating nasal polyps targeting and blocking immunoglobulin E (IgE), that aids in decreasing the size of nasal polyps. This will support market expansion.
With ab expected increase in the launch of biologics in the upcoming years, the ratio of patients opting for surgery might decline because of the excellent effectiveness of biologics and also fewer possibility of recurrence of the disease, augmenting the industry’s growth. Furthermore, the surge in market size of Nasal Polyposis is a direct result of the anticipated approval of emerging therapies and the rising Nasal Polyposis patient population.
Principal Consultant
Dearth of Skilled Professionals and High Cost of Treatment will restrain market growth
Dearth of skilled and qualified healthcare professionals who are not able to treat these patients with appropriate treatments could hold back growth of the global nasal polyposis drugs market during the projected period. The massive expenditure associated with nasal polyposis treatment is also expected to hinder market expansion.
On the other hand, factors such as bleeding, visual disturbances, inflammation, and cerebrospinal fluid leak linked with surgical removal of nasal polyposis and several adverse reactions because of steroid therapy, may restrain market growth.
Rising Incidence of Chronic Rhinosinusitis to encourage Patients to Opt for Treatment
North America is anticipated to dominate the nasal polyposis treatment market, capturing a 41.5% market share. This region is projected to reflect a CAGR of 6.1% from 2023 to 2033. The growth is attributable to increasing incidence of several cancers and allergic disorders like asthma, sinusitis, and others. Moreover, research activities in the United States coupled with surging approvals from regulatory bodies are anticipated to fuel growth of this market during the projected period.
The presence of a huge target population, affected by chronic rhinosinusitis with nasal polyposis and rising sinus surgeries conducted in the United States are the major factors attributed to hold dominance in this region. Additionally, the approvals by the Federal Agency for the reimbursement of money used for treatment of nasal polyps will aid in regional market expansion.
For example, in June 2020, Intersect ENT, a medical device company, was approved by Centers for Medicare and Medicaid Services to SINUVA Sinus Implant for reimbursement, with a New C–Code. Likewise, New C Code for SINUVA will simplify the reimbursement process for ENT physicians and their practices which will boost regional market expansion. It will provide Medicare patients easier access to this novel drug eluting sinus implant. This will support in regional expansion of the market.
Healthcare Providers finding Ground amid Increased Cases of Respiratory Disorders
According to Future Market Insights, Asia Pacific is expected to register a CAGR of 7% during the forecast period ranging from 2023 to 2033, with respect to treatment for nasal polyposis. The growth is expected to be driven by prevalence of allergic disorders and stable growth of the pharmaceutical industry in recent years. Moreover, China plays a crucial role in the Asia pacific region owing to its high population and high degree of government initiatives in the healthcare sector. Also, Ongoing trials in this region are expected to further stimulate market growth.
The presence of a large patient pool suffering from inflammatory and respiratory disorders in developing countries such as China and India, and growth in sinus surgeries conducted in developed countries in the region, are expected to fuel the nasal polyposis treatment market.
Similarly, increasing number of patients affected by nasal polyposis, government initiatives to promote awareness, and increasing demand for treatment are some of the other factors responsible for market expansion in this region. Presence of huge population is also one of the factors anticipated to positively influence nasal polyposis industry growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Demand for Corticosteroids to Surge Prolifically in the Coming Decade
By type of treatment, corticosteroids are projected to account for 55% of all approaches. It is projected to witness CAGR of 9% during the forecast period. The growth is attributed to rising demand for corticosteroids treatment and its availability in numerous dosage forms such as injections, intranasal sprays, and drops according to suitability of the patient.
Furthermore, the availability of various corticosteroids as topical formulations and aerosols which have the ability to reduce the size of nasal polyposis, and therefore heal the nasal polyps in suffered patients is expected to contributed in significant share of market revenue. Likewise, Nasonex (mometasone) and Xhance (fluticasone propionate) are two major corticosteroid brands available in the market that will boost market growth. Also, patient compliance for creams is more compared to other dosage forms. This will aid in growth of the segment during the forecast period.
Hospitals to be the Primary Point of Contact for seeking Nasal Polyposis Treatment
Hospitals are anticipated to lead the market when it comes to seeking treatment for nasal polyps, with an expected market share of 64.2%. The growth of this segment is attributed to surging demand for sinus surgeries for the removal of nasal polyposis, leading to increased hospitalization and extensive range of services provided by hospitals at a single site.
Start-ups help in understanding the outlook of any market. Start-ups also have the potential to generate higher returns which directly benefits in expansion of any market. This is because these are typically more efficient at converting inputs into outputs. These are more flexible and adaptable, able to shift quickly in response to changing market conditions. Some of the start-ups that will aid in expansion of Nasal Polyposis treatment market are:
The nasal polyposis treatment market is competitive and consists of several major players. Major players are creating novel delivery systems for the treatment of nasal polyps. This is expected to propel nasal polyposis treatment market. The major players in the market are: Sanofi, Merck & Co, Inc., OptiNose US, Inc., Intersect ENT, Inc., Pfizer, Regeneron Pharmaceuticals, Inc., Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Inc.
Some recent developments in the market are:
Key market players are concentrating on adoption of inorganic growth strategies such as acquisition, partnerships, and collaboration in order to improve its product portfolio. This is anticipated to drive the global Nasal Polyposis treatment market.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 4.6 billion |
| Market Value in 2033 | US$ 8.8 billion |
| Growth Rate | CAGR of 6.7 % from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The projected CAGR of the nasal polyposis treatment market by 2033 is 6.7%.
The projected market value for 2033 is US$ 8.8 billion.
The market is estimated to secure a valuation of US$ 4.6 billion in 2023.
The key consumer of the nasal polyposis treatment market is the healthcare industry.
The North America market is growing remarkably fast due to the increasing prevalence of nasal polyposis.
1. Executive Summary | Nasal Polyposis Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type of Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type of Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type of Treatment, 2023 to 2033
5.3.1. Pharmacological Therapies
5.3.1.1. Corticosteroids
5.3.1.2. Antibiotics
5.3.1.3. Leukotriene Inhibitors
5.3.1.4. Others
5.3.2. Surgeries
5.3.2.1. Polypectomy
5.3.2.2. Functional Endoscopic Sinus Surgery
5.4. Y-o-Y Growth Trend Analysis By Type of Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Type of Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
6.3.1. Hospitals
6.3.2. Ambulatory Surgical Centres
6.3.3. Specialty Clinics
6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. United States
8.2.1.2. Canada
8.2.2. By Type of Treatment
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Type of Treatment
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Type of Treatment
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type of Treatment
9.3.3. By End User
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Type of Treatment
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type of Treatment
10.3.3. By End User
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Type of Treatment
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type of Treatment
11.3.3. By End User
11.4. Key Takeaways
12. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of Middle East and Africa
12.2.2. By Type of Treatment
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type of Treatment
12.3.3. By End User
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. United States
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Type of Treatment
13.1.2.2. By End User
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Type of Treatment
13.2.2.2. By End User
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Type of Treatment
13.3.2.2. By End User
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Type of Treatment
13.4.2.2. By End User
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Type of Treatment
13.5.2.2. By End User
13.6. United Kingdom
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Type of Treatment
13.6.2.2. By End User
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Type of Treatment
13.7.2.2. By End User
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Type of Treatment
13.8.2.2. By End User
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Type of Treatment
13.9.2.2. By End User
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Type of Treatment
13.10.2.2. By End User
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Type of Treatment
13.11.2.2. By End User
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Type of Treatment
13.12.2.2. By End User
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Type of Treatment
13.13.2.2. By End User
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Type of Treatment
13.14.2.2. By End User
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Type of Treatment
13.15.2.2. By End User
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Type of Treatment
13.16.2.2. By End User
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Type of Treatment
13.17.2.2. By End User
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Type of Treatment
13.18.2.2. By End User
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Type of Treatment
13.19.2.2. By End User
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Type of Treatment
13.20.2.2. By End User
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Type of Treatment
14.3.3. By End User
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Sanofi S.A
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Merck & Co, Inc.
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. OptiNose US, Inc.
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Intersect ENT, Inc.
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Pfizer Inc
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Regeneron Pharmaceuticals, Inc.
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Novartis AG
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. GlaxoSmithKline plc
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. F. Hoffmann-La Roche Ltd
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Teva Pharmaceutical Industries Inc
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Explore Healthcare Insights
View Reports
Nasal Polyposis Treatment Market
